Prime Medicine PRME Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's business segments — net loss?
- Prime Medicine (PRME) reported business segments — net loss of -$49.12M in Q1 2026.
- How has Prime Medicine's business segments — net loss changed year-over-year?
- Prime Medicine's business segments — net loss increased by 5.3% year-over-year, from -$51.89M to -$49.12M.
- What is the long-term trend for Prime Medicine's business segments — net loss?
- Over 2 years (2023 to 2025), Prime Medicine's business segments — net loss has grown at a 0.8% compound annual growth rate (CAGR), from -$198.13M to -$201.14M.
- What does business segments — net loss mean?
- Indicates the bottom-line financial result for a business segment when total operating expenses exceed total revenues. For early-stage biotechnology companies, this metric is a standard measure of the capital required to fund ongoing research and development efforts. It highlights the segment's current reliance on external funding or corporate-level support.